

**UNITED STATES
CRITICAL LIMB ISCHEMIA BY RUTHERFORD CATEGORY
PREVALENCE AND MARKETS
IN PATIENTS AND LIMBS**

Mary L. Yost
THE SAGE GROUP
404-520-6652

THE SAGE GROUP, LLC
23 Ridge Rd
Beaufort, SC

Copyright Pending
December 2017

All rights reserved, including the right of reproduction
in whole or in part in any form.

INDEX OF TABLES

Table 1: 2015 United States Prevalence of Peripheral Artery Disease and Critical Limb Ischemia Patients In the Adult Population Ages 45 and Older	5.
Table 2: Critical Limb Ischemia Percentage Prevalence by Rutherford Category	6.
Table 3: Critical Limb Ischemia Treatment Pathway by Rutherford Category	6.
Table 4: United States 2015-2030 Peripheral Artery Disease and Critical Limb Ischemia Patient Prevalence* and Number of Critically Ischemic Limbs in High Series	7.
Table 5: United States 2015-2030 High Series Critical Limb Ischemia Patient Prevalence by Rutherford Category	8.
Table 6: United States 2015-2030 High Series Critical Limb Ischemia Prevalence in Number of Limbs by Rutherford Category	8.
Table 7: United States 2015-2030 Rutherford Category 4 High Series Prevalence of Critically Ischemic Patients by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	9.
Table 8: United States 2015-2030 Rutherford Category 4 High Series Prevalence of Critically Ischemic Limbs by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	9.
Table 9: United States 2015-2030 Rutherford Category 4 High Series Critically Ischemic Patient Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	10.
Table 10: United States 2015-2030 Rutherford Category 4 High Series Critically Ischemic Limb Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	10.
Table 11: United States 2015-2030 Rutherford Category 5 High Series Prevalence of Critically Ischemic Patients by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	11.
Table 12: United States 2015-2030 Rutherford Category 5 High Series Prevalence of Critically Ischemic Limbs by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	11.
Table 13: United States 2015-2030 Rutherford Category 5 High Series Critically Ischemic Patient Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	12.
Table 14: United States 2015-2030 Rutherford Category 5 High Series Critically Ischemic Limb Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	12.
Table 15: United States 2015-2030 Rutherford Category 6 High Series Prevalence of Critically Ischemic Patients by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	13.

Table 16: United States 2015-2030 Rutherford Category 6 High Series Prevalence of Critically Ischemic Limbs by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	13.
Table 17: United States 2015-2030 Rutherford Category 6 High Series Critically Ischemic Patient Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	14.
Table 18: United States 2015-2030 Rutherford Category 6 High Series Critically Ischemic Limb Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	14.
Table 19: United States 2015-2030 Peripheral Artery Disease and Critical Limb Ischemia Patient Prevalence and Number of Critically Ischemic Limbs* in the Low Series	15.
Table 20: United states 2015-2030 Low Series Critical Limb Ischemia Prevalence in Number of Patients by Rutherford Category	16.
Table 21: United States 2015-2030 Low Series Critical Limb Ischemia Prevalence in Number of Limbs by Rutherford Category	16.
Table 22: United States 2015-2030 Rutherford Category 4 Low Series Prevalence of Critically Ischemic Patients by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	17.
Table 23: United States 2015-2030 Rutherford Category 4 Low Series Prevalence of Critically Ischemic Limbs by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	17.
Table 24: United States. 2015-2030 Rutherford Category 4 Low Series Critically Ischemic Patient Market by Treatment Pathway Revascularization, Primary Amputation and Palliative Therapies	18.
Table 25: United States 2015-2030 Rutherford Category 4 Low Series Critically Ischemic Limb Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	18.
Table 26: United States 2015-2030 Rutherford Category 5 Low Series Prevalence of Critically Ischemic Patients by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	19.
Table 27: United States 2015-2030 Rutherford Category 5 Low Series Prevalence of Critically Ischemic Limbs by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	19.
Table 28: United States 2015-2030 Rutherford Category 5 Low Series Critically Ischemic Patient Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	20.
Table 29: United States 2015-2030 Rutherford Category 5 Low Series Critically Ischemic Limb Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	20.
Table 30: United States 2015-2030 Rutherford Category 6 Low Series Prevalence of Critically Ischemic Patients by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	21.

Table 31: United States 2015-2030 Rutherford Category 6 Low Series Prevalence of Critically Ischemic Limbs by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	21.
Table 32: United States 2015-2030 Rutherford Category 6 Low Series Critically Ischemic Patient Market by Treatment Pathway: Revascularization, Primary Amputation and Palliative Therapies	22.
Table 33: United States 2015-2030 Rutherford Category 6 Low Series Critically Ischemic Limb Market by Treatment Pathway Revascularization, Primary Amputation and Palliative Therapies	22.
Table 34: HCUP Critical Limb Ischemia Inpatient Analysis 1998, 2007 & 2008 Number of Patients by Rutherford Category (ICD-9 Diagnosis Code)	24.
Table 35: HCUP Critical Limb Ischemia Inpatient Analysis 1998, 2007 & 2008 Percentage of Patients by Rutherford Category	25.

CONTACT INFORMATION

Research

Mary L. Yost
President and Senior Analyst
Telephone (404) 520-6652
yost@thesagegroup.us

Marketing

Harrington Witherspoon
Senior Vice President
Marketing
Telephone (404) 816-0746
witherspoon@thesagegroup.us